More than 2 million EVO lenses have been distributed worldwide. Use of the procedure, which no longer requires a peripheral iridotomy thanks to a central port in the middle of the lens, is expanding. It is not just for patients who are not suitable for laser vision correction. Surgeons have reported excellent results for the treatment of as low as -3.00 D of myopia.1 EVO is becoming an excellent option for patients with low and moderate myopia.
THE MYOPIA EPIDEMIC
Myopia is a global epidemic. In 2020, an estimated 34% of the global population was myopic, and it is expected to grow to 50% by 2050.2 Assuming the estimates are accurate, about 70 million people are currently living with myopia. Six million frequent replacement contact lens wearers drop out each year in the United States alone.3,4 The volume of patients searching for myopic surgical solutions therefore should continue to increase (Figure 1).
There is ample room for all refractive surgical technologies in your practice. Offering a variety of solutions, including EVO, can synergistically bring more patients into your clinics for refractive solutions. The following articles share advice from experts who have experience with EVO. They touch on patient selection, patient education, preoperative examinations, intraoperative pearls, patient outcomes, and growing your practice with EVO.
1. Packer M. The EVO ICL for moderate myopia: results from the US FDA clinical trial. Clin Ophthalmol. 2022;16:2981-3991.
2. Holden BA, Wilson DA, Jong M, et al. Myopia: a growing global problem with sight-threatening complications. Community Eye Health. 2015;28(90):35.
3. Nguyen TL. How to reduce contact lens dropouts. June 28, 2017. Accessed April 20, 2023. https://www.reviewob.com/4-steps-to-reduce-contact-lens-dropouts-increase-profitability/
4. Rumpakis J. New data on contact lens dropouts: an international perspective. January 15, 2010. Accessed April 20, 2023. https://www.reviewofoptometry.com/article/new-data-on-contact-lens-dropouts-an-international-perspective